Current status: Phase 3 trials (expected to continue through 2025-2026) FDA approval timeline: Likely 2026-2027 at the earliest What needs to happen first: Complete Phase 3 trials in larger populations Gather long-term safety data FDA review and approval process Manufacturing scale-up So while the results are exciting, we're still a few years away from retatrutide being available by prescription
How does Gentle Patches GLP-1 compare to prescription medications
The following GLP-1 (glucagon-like peptide-1) receptor agonists are FDA-approved for weight loss:[ref] Retatrutide is a GLP-1/GIP/GCG triple agonist that is currently in trials for weight loss and diabetes, showing promise for weight loss without muscle loss (2026)
As Aons own researchers put it, that is not just a win for patients
Using expired semaglutide is not recommended for many reasons, including: Reduced Effectiveness Medications have expiration dates on their labels that display the time frame they should be used by to ensure they maintain their full potency and are still safe to use
Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity
/assets/images/provider/photos/2775905.jpeg)
